Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Carcinoma, Medullary 4Thyroid Neoplasms 2Neoplasm Metastasis 2Familial medullary thyroid carcinoma 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × vandetanib × 1 year × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Sanofi

Phase 4 Completed
81 enrolled 15 charts
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Sanofi

Phase 3 Completed
331 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡